Michael Crowley, Head Of Business Development Roche .
Roche Company PresentationMichael Crowley, Head of Business Development RocheResearch & Early Development, Pharma Partnering
The Roche Group: aninnovation-driven companyWhy we make agood partnerWhat we are lookingfor from you2
The Roche Group: aninnovation-driven companyWhy we make agood partnerWhat we are lookingfor from you3
The Roche GroupA leading healthcare company dedicated to innovation in a sustainable way189661.5 bnFounded in BaselFamily still holdsmajority stakeBiotechSales 2019 (CHF) 197’735R&D investor inhealthcareEmployees worldwideLasting 30 medicineson World HealthOrganization List ofEssential Medicines1 GenentechGenentech1, firstpublicly-ownedbecame a full member of the Roche group in March 200963,000,000people treatedworldwide with ourmedicines in 2019 and Sustainable36Among top companies in Dow JonesSustainability Index (Life Sciences Sector)for 10 consecutive yearsFDA BreakthroughDesignations4
The leader in personalized healthcareOptimally positioning us for the futureCombiningpharmaceuticals anddiagnostics under one rooftogether with deep know-howin molecular biology and datascience, make Roche aunique partner to drive nextstep in the evolutionof healthcare.Leader in PharmaLeader in DiagnosticsDiagnosisDecision SupportTherapyTherapy monitoring5
Our unique innovation modelProviding scientific freedom to work, think and address problemsin different waysResearch and Early DevelopmentLate Stage and Commercial (Pharma)gREDGlobal lizationIndependent Centers forResearch and Early DevelopmentRoche Pharma PartneringManaging over 220 partnershipsWorldwide execution6
The Roche Group: aninnovation-driven companyWhy we make agood partnerWhat we are lookingfor from you7
Global presencePharma Partnering officesCambridgeSouth San FranciscoBostonBaselTokyoShanghaiWith around 120 people worldwide, Pharma Partneringoffers speed, flexibility and accessibility to partners.8
Our approach to Partnering in the Pharma industryWe value external innovation and bring our experts to the table9
Because a great idea is a great idea no matter where it comes from 50%of R&D pipelineinvolve a partnership 40%of total Pharma salesgenerated from partneredor in-licensed products10
Roche launched 20 new molecules since 201115 out of the 20 are partnered medicines2011Partnered medicines20122013201420152016201720182019202011
We value external innovationComplementing our internal innovation and expertise211AcquisitionsProductout-licensing agreementsand divestments16Agreements derived fromexisting alliances14Product, technologyor discovery licenseagreements7819new agreementsin 2019PHC agreementsAgreements entered in:››››OncologyImmunologyOphthalmologyGene therapy››››NeurologyTechnology PlatformsPHCRare Diseases16Research and technologyand clinical trial collaborations12
The Roche Group: aninnovation-driven companyWhy we make agood partnerWhat we are lookingfor from you13
Our focus areasSeeking great science across multiple therapeutic areasDigital &Personalized Healthcare Robust data sets Advanced Analytics (artificialintelligence incl. machinelearning and deep-learningmodels)Immunology Gastroenterology, Respiratory,Rheumatology Innate, Adaptive, Fibrosis,Tolerance and TissueRegeneration TargetsInfectiousDiseasesNeuroscience Hepatitis B Neurodegeneration (e.g. AD,Parkinson's disease, HD, ALS) Respiratory Viruses Neuroinflammation (e.g. MS) Multidrug-resistant, Gramnegative Bacterial Infections Neurodevelopmental (e.g. ASD) Pain (non-opioid treatments forchronic pain) Digital and mobile technologiesOncology & CancerImmunotherapy Oncogenic drivers Synthetic lethality Adaptive and innate immunity NeoantigensOphthalmology Retinal diseases and longacting ocular drug deliverysolutions Glaucoma and dry eye diseaseRare Diseases Monogenetic rare diseasesResearchTechnologies Novel modalities & enablingtechnologies to expanddruggable target space Targeted, intracellular delivery Stromal biology Artificial intelligence for drugdiscovery Cell therapies Genomic Medicine platforms14
15
Doing now what patients need next16
Michael Crowley, Head of Business Development Roche Research & Early Development, Pharma Partnering Roche Company Presentation. 2 The Roche Group: an innovation-driven company Why we make a good partner What we are looking for from you. 3 What we are looking The Roche Group: an for from you
Crowley and some of the carbon copies of the letters Crowley sent to Pessoa. 2 In the preface of an edition of these documents, Pessoa’s nephew, Luis Miguel Rosa Dias noted that “as cartas de Aleister Crowley e as cópias da correspondência de Fernando Pessoa [ ] não foram publicadas há
Crowley failed to appear at the Show Cause hearing scheduled for August 30, 2001. The Board voted to continue the summary suspension and Ms. Crowley requested a hearing on the merits, which was scheduled for February 14, 2002. On or about October 10, 2001 the Board charged Ms. Crowley with violations of
Each newspaper also has the same information as the . Crowley Crowley post herald 1966? 1974 1967 1974 1968,1970-1974 -3163 Rayne Rayne independent* 1967 present 1967 present 1967-present -3100 Crowley Crowley post-signal 1974 present 1974 present 1974-2004 -0633 Friday, September 07, 2012 .
Crowley called on Mr. O’Brien a few days later, he was absent. However, Crowley discovered he was in the offices of a weekly newspaper called The Fatherland. Crowley described the person who first took charge of his visit as a “little amniote—half rat,
Aleister Crowley, May 25, 1923, The Magical Diaries of Aleister Crowley 19232 O NE of the most striking aspects of the occultist Aleister Crowley’s voluminous fin de siècle poetry is the scale on which its brazen erot-icism looks at once unmatched in its outrageousness and deplorable in its ineptitude.
Crowley The spread of the Crowley surname by county in Griffith’s Valuation is in tabular form: We can see that the surname is spread throughout much of the country with the significantly larger number in County Cork at 1,019 followed by Kerry at 105 and Waterford at 58. Census of Ireland 1901 County Number Limerick 22 Queen's County (Laois) 3
in Crowley’s own 777. The editor has assumed that Crowley intended to incorporate these in the new edition. For the few interested in Gematria the numerical values of the Greek and Arabic alphabets have been added.ƒ Crowley never completed 777 Revised, but he left enough material to justify its posthumous publication. N
Part 2, Design – High Strength Steels was combined with Part 1, Design in 1993. Part 5, Special Types of Construction was combined with Part 1, Design in 2008. Part 10, Bearing Design, and Part 11, Bearing Construction, were combined into a new Part 5, Bearing Design and Construction in 2013.
